Get the Stockscreener App
4.114
2.85%
0.114
Atea Pharmaceuticals Inc stock is traded at $4.114, with a volume of 304.26K.
It is up +2.85% in the last 24 hours and up +12.71% over the past month.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
See More
Previous Close:
$4.00
Open:
$3.98
24h Volume:
304.26K
Relative Volume:
0.74
Market Cap:
$321.49M
Revenue:
$351.37M
Net Income/Loss:
$-174.01M
P/E Ratio:
-1.9874
EPS:
-2.07
Net Cash Flow:
$-126.94M
1W Performance:
+19.59%
1M Performance:
+12.71%
6M Performance:
+5.49%
1Y Performance:
+30.60%
1-Day Range:
$3.93
$4.15
1-Week Range:
$3.41
$4.3399
52-Week Range:
$2.455
$4.3399
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
857-204-8109
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
4.115 | 312.51M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.09 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
866.10 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.40 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Institutional Investors Are Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Biggest Bettors and Were Rewarded After Last Week's US$56m Market Cap Gain - 富途牛牛
Can Atea Pharmaceuticals Inc expand into new marketsEarnings Recap Report & Risk Managed Trade Strategies - baoquankhu1.vn
Spotlight On Atea Pharmaceuticals And 2 Other Noteworthy Penny Stocks - Yahoo Finance
Is Atea Pharmaceuticals Inc. still a buy after recent gainsBlue Chip Stock Analysis & Daily Tips From Top Market Analysts - bollywoodhelpline.com
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens - Pharmaceutical Technology
Dip Buying: Can Atea Pharmaceuticals Inc stock double in the next year2025 Bull vs Bear & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Buyout Rumor: Is Atea Pharmaceuticals Inc a momentum stockTrend Reversal & Expert Curated Trade Setups - baoquankhu1.vn
Wall Street Recap: Will Atea Pharmaceuticals Inc face regulatory challengesTrade Volume Report & Long-Term Investment Growth Plans - baoquankhu1.vn
Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference - MarketBeat
Options Flow: Will Atea Pharmaceuticals Inc stock maintain dividend yieldJuly 2025 Patterns & Smart Money Movement Tracker - Bộ Nội Vụ
Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock - Yahoo Finance
How Atea Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Technicals & Entry Point Confirmation Alerts - Улправда
What is the fair value of Atea Pharmaceuticals Inc. stock nowEarnings Miss & Community Consensus Stock Picks - ulpravda.ru
Risk Off: Will Atea Pharmaceuticals Inc stock attract more institutional investorsTrade Exit Report & Risk Adjusted Buy/Sell Alerts - Bộ Nội Vụ
Atea Pharmaceuticals to highlight strategic priorities for FY26 - Yahoo Finance
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Will Atea Pharmaceuticals Inc. stock attract more institutional investorsTrade Ideas & Safe Capital Growth Stock Tips - ulpravda.ru
Why Atea Pharmaceuticals Inc. stock is popular among millennials2025 Trading Volume Trends & Community Consensus Trade Alerts - Улправда
Will Atea Pharmaceuticals Inc. stock deliver strong dividend growthGlobal Markets & Precise Buy Zone Identification - ulpravda.ru
Atea Pharmaceuticals Highlights 2026 Strategic Priorities - TradingView — Track All Markets
Atea Pharmaceuticals Advances Phase 3 Trials for HCV Treatment Regimen, Anticipates Significant Milestones in 2026 - Quiver Quantitative
New hepatitis C and E treatments move toward key human clinical trials in 2026 - Stock Titan
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Is Atea Pharmaceuticals Inc. stock supported by strong cash flows2026 world cup usa national team qualification star players pressing system winner prediction breakdown - ulpravda.ru
Critical Survey: Atea Pharmaceuticals (NASDAQ:AVIR) vs. Regeneron Pharmaceuticals (NASDAQ:REGN) - Defense World
What analysts say about Atea Pharmaceuticals Inc stockTrading Volume Trends & Build a Smarter Portfolio Right Now - earlytimes.in
What drives Atea Pharmaceuticals Inc stock priceWeekly Market Snapshot & Access Free Risk Analysis Before You Invest - earlytimes.in
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4%Here's What Happened - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4% – Here’s What Happened - Defense World
Rapt Therapeutics (NASDAQ:RAPT) & Atea Pharmaceuticals (NASDAQ:AVIR) Head-To-Head Contrast - Defense World
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - Sahm
Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs? - RTTNews
Atea Pharmaceuticals Completes Enrollment in North American Phase 3 Trial of Hepatitis C Treatment - marketscreener.com
Atea Pharmaceuticals Completes Enrollment in C-BEYOND Phase 3 Trial for HCV Treatment, Anticipates Topline Results in Mid-2026 - Quiver Quantitative
Atea Pharmaceuticals Completes Patient Enrollment In North American Phase 3 Trial Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - TradingView — Track All Markets
Atea Pharmaceuticals Completes Patient Enrollment in North - GlobeNewswire
Published on: 2025-12-21 17:47:39 - Улправда
Why analysts upgrade Atea Pharmaceuticals Inc. stockEarnings Overview Report & Stepwise Swing Trade Plans - Улправда
Is Atea Pharmaceuticals Inc. stock attractive for ETFsJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
What technical charts say about Atea Pharmaceuticals Inc. stockJuly 2025 Breakouts & Safe Capital Growth Plans - Улправда
How rising interest rates impact Atea Pharmaceuticals Inc. stockEntry Point & Long Hold Capital Preservation Plans - DonanımHaber
Will Atea Pharmaceuticals Inc. stock maintain growth storyTrade Performance Summary & Free Real-Time Volume Trigger Notifications - DonanımHaber
Chart Watch: Is Atea Pharmaceuticals Inc. stock supported by strong cash flowsJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - Улправда
Nano Dimension And 2 Other Penny Stocks With Promising Potential - simplywall.st
Atea Pharmaceuticals Earnings Notes - Trefis
Atea Pharmaceuticals (AVIR) Stock Analysis Report | Financials & Insights - Benzinga
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 1.9%Should You Sell? - MarketBeat
We're Keeping An Eye On Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Rate - Yahoo Finance
How Atea Pharmaceuticals Inc. stock trades during market volatilityTrade Risk Assessment & Community Verified Trade Signals - Newser
Is Atea Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Macro Moves & Daily Growth Stock Tips - Newser
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atea Pharmaceuticals Inc Stock (AVIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
2.05%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):